Yoshinari Tanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshinari Tanabe has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Bin Chang
3 shared publicationsKengo Oshima
3 shared publicationsKosuke Tamura
3 shared publicationsTakaya Maruyama
3 shared publicationsEiichi Suzuki
Department of General Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
2 shared publicationsFumitake Gejyo
Division of Respiratory Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Elsevier in SSRN Electronic Journal
Estimation of preventable pneumococcal disease burden by PCV20 or PCV21 under the national immunization program for adults aged 65 years in Japan
Background: 21-valent pneumococcal conjugate vaccine (PCV21) is under evaluation, in comparison to PCV20, for the routine immunization among adults aged 65-year in Japan. Methods: Serotype distribution of isolates and the incidence of invasive pneumococcal disease (IPD) in adults were monitored yearly, and the case numbers of IPD or pneumococcal community-acquired pneumonia (pCAP) preventable by immunization with PCV20 or PCV21 were estimated according to the reported vaccine efficacy and it’s duration in older adults. Data from our study of nationwide adult IPD surveillance and a multicenter study of pCAP were used.Results: The mean annual incidence of adult patients with IPD caused by all serotypes in the 65-year age group, which declined during COVID-19 pandemic period, returned to 89% of that before pandemic in 2025. The proportion of PCV20-nonPCV21 serotype was 8.5% in adults aged 65 years during the period of 2023–2025. At a current vaccination coverage rate of 40%, the numbers of preventable IPD cases (person per year) by PCV20 and PCV21 were 36 and 53, respectively. The preventable numbers of pCAP cases (person per year) by PCV20 and PCV21 were 2,821 and 4,765, respectively. The preventable number of pCAP cases was approximately 80 to 90 times higher than that of IPD cases.Conclusion: Our data indicate that PCV21 is 1.5–1.7 time more preventable than those of PCV20 in adults aged 65 years in Japan. PCV20 should be considered in case of increased adult IPD cases with PCV20–nonPCV21 serotype.
- 12 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEstimation of preventable pneumococcal disease burden by PCV20 or PCV21 under the national immunization program for adults aged 65 years in Japan
Background: 21-valent pneumococcal conjugate vaccine (PCV21) is under evaluation, in comparison to PCV20, for the routine immunization among adults aged 65-year in Japan. Methods: Serotype distribution of isolates and the incidence of invasive pneumococcal disease (IPD) in adults were monitored yearly, and the case numbers of IPD or pneumococcal community-acquired pneumonia (pCAP) preventable by immunization with PCV20 or PCV21 were estimated according to the reported vaccine efficacy and it’s duration in older adults. Data from our study of nationwide adult IPD surveillance and a multicenter study of pCAP were used.Results: The mean annual incidence of adult patients with IPD caused by all serotypes in the 65-year age group, which declined during COVID-19 pandemic period, returned to 89% of that before pandemic in 2025. The proportion of PCV20-nonPCV21 serotype was 8.5% in adults aged 65 years during the period of 2023–2025. At a current vaccination coverage rate of 40%, the numbers of preventable IPD cases (person per year) by PCV20 and PCV21 were 36 and 53, respectively. The preventable numbers of pCAP cases (person per year) by PCV20 and PCV21 were 2,821 and 4,765, respectively. The preventable number of pCAP cases was approximately 80 to 90 times higher than that of IPD cases.Conclusion: Our data indicate that PCV21 is 1.5–1.7 time more preventable than those of PCV20 in adults aged 65 years in Japan. PCV20 should be considered in case of increased adult IPD cases with PCV20–nonPCV21 serotype.
- Open Access
- 5 April 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 143, 107024
Unveiling the role of preceding seasonal influenza in the development of bacteremic pneumococcal pneumonia in older adults before the COVID-19 pandemic in Japan
- 5 April 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 143, 107024
Open AccessUnveiling the role of preceding seasonal influenza in the development of bacteremic pneumococcal pneumonia in older adults before the COVID-19 pandemic in Japan
- Open Access
- 9 August 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-6
Case report: pulmonary nocardiosis caused by Nocardia exalbida in an immunocompetent patient
Background: Nocardiosis is known as an opportunistic infection in immunocompromised hosts, but it occasionally has been reported in immunocompetent patient. The Nocardia exalbida is first-reported in 2006 from Japan, and a few cases of have been reported in only immunocompromised host, and the characteristic is still unclear. We herein describe the first case of pulmonary nocardiosis caused by N. exalbida in an immunocompetent patient. Case presentation: A77 -year-old Japanese man was admitted to our hospital on November 2, 2018. He was a lifelong non-smoker with no childhood history of respiratory disease. He had a medical history of dyslipidemia. One month before this admission fevers, sputum, mild cough were developed and he was evaluated in a clinic near our hospital. His diagnosis was community acquired pneumonia within his right middle lobe. He was treated with ceftriaxone 1 g/day intravenously for a week, however his symptoms relapsed a few days later. So, the physician retried ceftriaxone for another 3 days, but his symptoms did not improve. He was referred to our hospital. He was treated with sitafloxacin as an outpatient for a week, however his symptoms got worse. The chest CT showed consolidation and atelectasis in his right middle lobe. Low density area was scattered in consolidation, and right pleural effusion was observed. The patient was diagnosed with pulmonary abscess and he was admitted. Administration of piperacillin/tazobactam improved his condition. We switched antibiotics to amoxicillin/clavulanate, and he was discharged. After 2 weeks, he relapsed and was admitted again. After administration of piperacillin/tazobactam for 3 weeks, we perform bronchoscopy and Nocardia species were cultured from samples of the bronchial wash. The isolates were identified as N. exalbida using 16S rRNA gene sequencing. We prescribed Trimethoprim / Sulfamethoxazole (TMP/SMX) for 4 months. Then we switched to minocycline for renal dysfunction caused from TMP-SMX for 1 more month. After 5 months therapy, Consolidation on CT disappeared, and Nocardiosis was cured. Conclusion: we reported the first case of pulmonary nocardiosis caused by N. exalbida in an immunocompetent patient. N. exalbida infection might be associated with a good response to treatment.
- 9 August 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-6
Open AccessCase report: pulmonary nocardiosis caused by Nocardia exalbida in an immunocompetent patient
Background: Nocardiosis is known as an opportunistic infection in immunocompromised hosts, but it occasionally has been reported in immunocompetent patient. The Nocardia exalbida is first-reported in 2006 from Japan, and a few cases of have been reported in only immunocompromised host, and the characteristic is still unclear. We herein describe the first case of pulmonary nocardiosis caused by N. exalbida in an immunocompetent patient. Case presentation: A77 -year-old Japanese man was admitted to our hospital on November 2, 2018. He was a lifelong non-smoker with no childhood history of respiratory disease. He had a medical history of dyslipidemia. One month before this admission fevers, sputum, mild cough were developed and he was evaluated in a clinic near our hospital. His diagnosis was community acquired pneumonia within his right middle lobe. He was treated with ceftriaxone 1 g/day intravenously for a week, however his symptoms relapsed a few days later. So, the physician retried ceftriaxone for another 3 days, but his symptoms did not improve. He was referred to our hospital. He was treated with sitafloxacin as an outpatient for a week, however his symptoms got worse. The chest CT showed consolidation and atelectasis in his right middle lobe. Low density area was scattered in consolidation, and right pleural effusion was observed. The patient was diagnosed with pulmonary abscess and he was admitted. Administration of piperacillin/tazobactam improved his condition. We switched antibiotics to amoxicillin/clavulanate, and he was discharged. After 2 weeks, he relapsed and was admitted again. After administration of piperacillin/tazobactam for 3 weeks, we perform bronchoscopy and Nocardia species were cultured from samples of the bronchial wash. The isolates were identified as N. exalbida using 16S rRNA gene sequencing. We prescribed Trimethoprim / Sulfamethoxazole (TMP/SMX) for 4 months. Then we switched to minocycline for renal dysfunction caused from TMP-SMX for 1 more month. After 5 months therapy, Consolidation on CT disappeared, and Nocardiosis was cured. Conclusion: we reported the first case of pulmonary nocardiosis caused by N. exalbida in an immunocompetent patient. N. exalbida infection might be associated with a good response to treatment.
- Open Access
- 25 May 2019
- Published by Japanese Society of Environmental Infections in Japanese Journal of Infection Prevention and Control
- Vol. 34 (3) , 162-168
Comparison of Ventilator-associated Event Surveillance and Conventional Ventilator-associated Pneumonia Surveillance
2013年に新定義のVentilator-Associated Events(VAE)サーベイランスが提唱されたが我が国における報告は限られている.我々は2013年12月1日から2016年3月31日に新潟大学医歯学総合病院のIntensive Care Unit(ICU)で人工呼吸器を使用した18歳以上の患者に対しVAEサーベイランスと旧定義Ventilator-Associated Pneumonia(VAP)サーベイランスを行い比較検討した.対象患者290例中Ventilator-Associated Conditions(VAC)14例,Infection-related Ventilator-Associated Complications(IVAC)7例,Possible VAP(PVAP)8例,旧定義VAP7例(発生率3.6,1.8,2.1,1.8/1000人工呼吸器使用日数)であった.非VAE非VAP例に比し,人工呼吸器使用日数・ICU滞在日数はPVAP例と旧定義VAP例で,総死亡率・ICU死亡率はVAC例とPVAP例で有意に高かった.旧定義VAP7例中VAEとの一致は4例で不一致の主な要因は酸素化の悪化が軽度でVAEの定義を満たさなかったことであった.VAEサーベイランスは旧定義VAP同定に対する感度は低いが我が国においても予後予測の面で有用である可能性がある.
- 25 May 2019
- Published by Japanese Society of Environmental Infections in Japanese Journal of Infection Prevention and Control
- Vol. 34 (3) , 162-168
Open AccessComparison of Ventilator-associated Event Surveillance and Conventional Ventilator-associated Pneumonia Surveillance
2013年に新定義のVentilator-Associated Events(VAE)サーベイランスが提唱されたが我が国における報告は限られている.我々は2013年12月1日から2016年3月31日に新潟大学医歯学総合病院のIntensive Care Unit(ICU)で人工呼吸器を使用した18歳以上の患者に対しVAEサーベイランスと旧定義Ventilator-Associated Pneumonia(VAP)サーベイランスを行い比較検討した.対象患者290例中Ventilator-Associated Conditions(VAC)14例,Infection-related Ventilator-Associated Complications(IVAC)7例,Possible VAP(PVAP)8例,旧定義VAP7例(発生率3.6,1.8,2.1,1.8/1000人工呼吸器使用日数)であった.非VAE非VAP例に比し,人工呼吸器使用日数・ICU滞在日数はPVAP例と旧定義VAP例で,総死亡率・ICU死亡率はVAC例とPVAP例で有意に高かった.旧定義VAP7例中VAEとの一致は4例で不一致の主な要因は酸素化の悪化が軽度でVAEの定義を満たさなかったことであった.VAEサーベイランスは旧定義VAP同定に対する感度は低いが我が国においても予後予測の面で有用である可能性がある.
- Open Access
- 1 January 2014
- Published by Japanese Society of Allergology in Allergology International
- Vol. 63 (1) , 67-74
Analysis of the Influenza A (H1N1) 2009 Pandemic Infection in Japanese Asthmatic Patients: Using a Questionnaire-Based Survey
Influenza infection is known to be an exacerbating factor in the control of asthma, therfore its prevention is critical in managing asthma. The aim of this study was to investigate the influenza A H1N1 2009 pandemic virus (H1N1 pdm09) infection in adult asthmatic patients. Data were obtained from a questionnaire-based survey of asthmatic patients conducted from September to October 2010 in Niigata Prefecture. Patient background, H1N1 pdm09 infection, vaccination status, and asthma exacerbation due to influenza infection were analyzed. In total, 2,555 cases were analyzed. The incidence of the infection was 6.7% (95% confidence interval [CI]: 5.7-7.6), and the rate of vaccination was 63.9% (95% CI: 62.1-65.8). The odds ratio (OR) for vaccination against the infection among adult patients and younger patients (≤ the median age) were 0.61 (95% CI: 0.45-0.84) and 0.62 (95% CI: 0.42-0.90), respectively. However, OR among the older patient (> median age) were 1.38 (95%CI: 0.66-2.89). The rate of infection-induced asthma exacerbation was 23.2% (95% CI: 18.6-29.6), and the OR for vaccination against the infection-induced asthma exacerbation was 1.42 (95% CI: 0.69-2.92). The effectiveness of the vaccination against the H1N1 pdm09 virus was confirmed during the first pandemic season, but it was limited. Further investigation on H1N1 pdm09 virus infection in asthmatics will be required.
- 1 January 2014
- Published by Japanese Society of Allergology in Allergology International
- Vol. 63 (1) , 67-74
Open AccessAnalysis of the Influenza A (H1N1) 2009 Pandemic Infection in Japanese Asthmatic Patients: Using a Questionnaire-Based Survey
Influenza infection is known to be an exacerbating factor in the control of asthma, therfore its prevention is critical in managing asthma. The aim of this study was to investigate the influenza A H1N1 2009 pandemic virus (H1N1 pdm09) infection in adult asthmatic patients. Data were obtained from a questionnaire-based survey of asthmatic patients conducted from September to October 2010 in Niigata Prefecture. Patient background, H1N1 pdm09 infection, vaccination status, and asthma exacerbation due to influenza infection were analyzed. In total, 2,555 cases were analyzed. The incidence of the infection was 6.7% (95% confidence interval [CI]: 5.7-7.6), and the rate of vaccination was 63.9% (95% CI: 62.1-65.8). The odds ratio (OR) for vaccination against the infection among adult patients and younger patients (≤ the median age) were 0.61 (95% CI: 0.45-0.84) and 0.62 (95% CI: 0.42-0.90), respectively. However, OR among the older patient (> median age) were 1.38 (95%CI: 0.66-2.89). The rate of infection-induced asthma exacerbation was 23.2% (95% CI: 18.6-29.6), and the OR for vaccination against the infection-induced asthma exacerbation was 1.42 (95% CI: 0.69-2.92). The effectiveness of the vaccination against the H1N1 pdm09 virus was confirmed during the first pandemic season, but it was limited. Further investigation on H1N1 pdm09 virus infection in asthmatics will be required.
- Open Access
- 1 January 2003
- Published by The Japanese Association for Infectious Diseases in Kansenshogaku Zasshi
- Vol. 77 (4) , 227-234
Comparison of Four Diagnostic Methods Using Clinical Blood by Measuring (1^|^rarr;3)-^|^beta;-D-Glucan
Using Amebocyte lysate of horseshoe crab to measure (1-->3)-beta-D-glucan specifically, a component of the cell wall, several kinds of diagnostic methods for deep mycosis are in practical use in Japan. However, the most important problem is that the judgment of positive or negative is method dependent. To elucidate the cause of the problem, each measurement value of the identical sample by four methods, beta-Glucan Test Maruha (MARUHA), beta-Glucan Test Wako (WAKO). FUNGITEC G Test (FUNGITEC-G) and FUNGITEC G Test MK (FUNGITEC-MK) was compared with the clinical data using 119 cases and 289 tests. Each case was divided into three groups; proven fungal infection, probable fungal infection and non-fungal infection. The negative cases for all the methods tested in the groups of proven fungal infection and probable fungal infection were allergic bronchopulmonary aspergillosis and cryptococcosis, and that for all the methods tested except FUNGITEC-MK method in the group was pulmonary aspergilloma. It seems that these cases cannot be detected correctly by only measuring (1-->3)-beta-D-glucan. On the other hand, the ratio of false positive, positive for non-fungal infection group was high in the case of FUNGITEC-MK. About 23% against the total case was positive for FUNGITEC-MK method, but negative for MARUHA, WAKO, and FUNGITEC-G methods. Although the difference of the sensitivity among four methods was not observed, the specificity, the diagnostic efficiency, and the positive predictive value of FUNGITEC-MK method were remarkably lower than those of the other methods due to false positive measurement. In conclusion, MARUHA, WAKO and FUNGITEC-G except FUNGITEC-MK is not method dependent. It is suggested that FUNGITEC-MK detects non-specific reaction resulted in false positive.
- 1 January 2003
- Published by The Japanese Association for Infectious Diseases in Kansenshogaku Zasshi
- Vol. 77 (4) , 227-234
Open AccessComparison of Four Diagnostic Methods Using Clinical Blood by Measuring (1^|^rarr;3)-^|^beta;-D-Glucan
Using Amebocyte lysate of horseshoe crab to measure (1-->3)-beta-D-glucan specifically, a component of the cell wall, several kinds of diagnostic methods for deep mycosis are in practical use in Japan. However, the most important problem is that the judgment of positive or negative is method dependent. To elucidate the cause of the problem, each measurement value of the identical sample by four methods, beta-Glucan Test Maruha (MARUHA), beta-Glucan Test Wako (WAKO). FUNGITEC G Test (FUNGITEC-G) and FUNGITEC G Test MK (FUNGITEC-MK) was compared with the clinical data using 119 cases and 289 tests. Each case was divided into three groups; proven fungal infection, probable fungal infection and non-fungal infection. The negative cases for all the methods tested in the groups of proven fungal infection and probable fungal infection were allergic bronchopulmonary aspergillosis and cryptococcosis, and that for all the methods tested except FUNGITEC-MK method in the group was pulmonary aspergilloma. It seems that these cases cannot be detected correctly by only measuring (1-->3)-beta-D-glucan. On the other hand, the ratio of false positive, positive for non-fungal infection group was high in the case of FUNGITEC-MK. About 23% against the total case was positive for FUNGITEC-MK method, but negative for MARUHA, WAKO, and FUNGITEC-G methods. Although the difference of the sensitivity among four methods was not observed, the specificity, the diagnostic efficiency, and the positive predictive value of FUNGITEC-MK method were remarkably lower than those of the other methods due to false positive measurement. In conclusion, MARUHA, WAKO and FUNGITEC-G except FUNGITEC-MK is not method dependent. It is suggested that FUNGITEC-MK detects non-specific reaction resulted in false positive.